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Abstract: Coinfection with hepatitis C virus (HCV) and HIV is an increasingly recognized 
clinical dilemma, particularly since the advent of highly active antiretroviral therapy. Several 
studies of this population have demonstrated both more rapid progression of liver disease and 
poorer overall prognosis compared to HCV monoinfected patients. Consensus guidelines, based 
primarily on the results of 4 major randomized trials, recommend treatment with peginterferon 
and ribavirin for 48 weeks in coinfected patients. However, this current standard of care is asso-
ciated with lower response rates to therapy than those seen in monoinfected patients. Important 
predictors of response include HCV genotype, pretreatment HCV RNA level, and presence 
of rapid virologic response (RVR) and early virologic response (EVR). Use of weight-based 
ribavirin dosing appears to be safe and enhances the likelihood of sustained virologic response 
(SVR). Adverse effects most commonly encountered are anemia and weight loss. Mitochondrial 
toxicity can occur in the setting of concomitant nucleoside reverse transcriptase inhibitor use, 
especially didanosine, abacavir, and zidovudine, and these should be discontinued before ini-
tiation of ribavirin therapy. Discontinuation of therapy should be considered in patients failing 
to demonstrate EVR, though ongoing trials are investigating a potential role for maintenance 
therapy in these patients. Peginterferon combined with weight-based ribavirin is appropriate 
and safe for treatment of HCV in HIV – HCV coinfected patients. This review summarizes the 
data supporting these recommendations.
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Introduction
Coinfection with hepatitis C virus (HCV) and HIV affects 200,000–300,000 individu-
als in the US alone (Sherman et al 2002). As the two viruses share a common route of 
transmission, the prevalence of chronic HCV among all HIV patients has been reported 
in the range of 25% to 30% (Thomas 2002). Among HIV patients with a history of 
intravenous drug use, prevalence rates rise as high as 75%–90% (Alter 2006). Rates 
of coinfection via sexual transmission are increasing (McGovern and Bica 2002). In 
Europe and the US, since the advent of highly active antiretroviral therapy (HAART), 
HCV-related liver disease has become one of the leading causes of morbidity and 
mortality in HIV patients (Puoti et al 1997; Bica et al 2001).
Persons with HIV coinfection tend to have higher HCV viral loads and are less 
likely to clear the HCV spontaneously (Daar et al 2001). Compared with HCV-
monoinfected patients, coinfected patients have a more rapid progression of hepatic 
ﬁ  brosis (Graham et al 2001); an increased risk of developing cirrhosis, decompensated 
liver disease, and HCC. In addition, they have persistently higher HCV viremia; and 
a higher risk of HAART-related hepatotoxicity (Benhamou et al 1999; McGovern 
and Bica 2002; Rauch et al 2005). Unlike HCV-monoinfected patients, HCV viral Therapeutics and Clinical Risk Management 2008:4(4) 790
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load appears to have prognostic signiﬁ  cance in coinfected 
patients, and emerging data indicate that it may be an impor-
tant predictive indicator of HIV disease progression (Daar 
et al 2001). Whether or not coinfection causes a poorer 
overall prognosis in HIV disease remains controversial 
(Greub et al 2000).
In addition to bearing a poorer prognosis, coinfected 
patients also have lower response rates to therapy than those 
with HCV alone. Thus, the appropriate management of HCV-
related chronic liver disease in HIV patients presents sub-
stantial challenges for even the most experienced clinicians. 
Prior to undertaking therapy, there are a number of issues 
for the physician to address. These include prioritization of 
HAART vs anti-HCV therapy, the role of liver biopsy, and 
interactions between, and hepatotoxicity of, HAART and 
anti-HCV therapy. These important considerations have 
recently been reviewed elsewhere (McGovern and Bica 
2007) This review will focus on the evidence guiding opti-
mal dosages and duration of therapy, predictors of response, 
and toxicity concerns once the decision to treat has been 
made. Maximizing response to HCV therapy in HIV – HCV 
coinfected patients ﬁ  rst requires a basic understanding of the 
therapeutic approach to HCV-monoinfection.
Therapy of chronic HCV
Sustained viral response (SVR), deﬁ  ned as a level of serum 
HCV RNA that is undetectable 24 weeks after the end of 
therapy, is the established goal of therapy in HCV infection. 
This benchmark has been shown to predict durable long-term 
response (Lau et al 1998). Furthermore eradication of circu-
lating HCV RNA has been shown to reduce liver injury and, 
more controversially, even reverse liver ﬁ  brosis (Poynard 
et al 2002). Histologic response – especially improvement 
of ﬁ  brosis and necroinﬂ  ammation – has been proposed as 
a secondary goal of therapy, particularly in HIV – HCV 
coinfected patients (Barreiro et al 2006). Finally, eradication 
of HCV RNA may decrease the risk of HAART-related 
hepatotoxicity (McGovern 2004; Labarga et al 2007).
Interferon
Type 1 interferons (IFNs) are naturally occurring cytokines 
that have important innate antiviral, antiproliferative, and 
immunomodulatory properties. To date, the alpha IFNs 
have yielded the most promising results as pharmaceutical 
agents. The human alfa IFN family consists of at least 15 
subtypes, ranging in molecular size from 17.5 kD to 23 kD, 
each containing 165 or 166 amino acids, with approximately 
80% sequence homology between members of the group 
of proteins (Wills 1990). When parenterally administered, 
IFN binds to and leads to dimerization of IFN cell-surface-
receptor subunits. Activation of the receptor-associated 
Janus-activated kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2) 
then, in turn, lead to activation of transcription proteins 1 and 
2 (STAT 1 and STAT 2). The activated STAT1/2 complex 
then migrates to the cell nucleus, forming a complex with 
IFN-regulatory factor 9 (IRF-9) where interaction with 
cellular DNA leads to expression of IFN-stimulated genes 
(ISGs). As a result, a wide variety of gene products, many of 
which are involved in antiviral activity, are expressed (Tilg 
1997; deVeer et al 2001; Sen 2001; Gale 2003; Bekisz et al 
2004; Feld and Hoofnagle 2005).
The addition of ribavirin, a synthetic guanosine analogue, 
to IFN signiﬁ  cantly improves response rates, particularly for 
patients with HCV genotypes 2 and 3 (McHutchison et al 
1998; Pol et al 2000). Ribavirin may have some inherent anti-
viral activity against HCV, but its importance as a therapeutic 
agent appears to be its ability to enhance viral mutagenesis 
during IFN therapy. However, ribavirin signiﬁ  cantly adds 
to the side effect proﬁ  le of HCV antiviral therapy regimens, 
particularly by causing hemolytic anemia. HCV treatment 
has been further enhanced by the attachment of polyethylene 
glycol to the IFN molecule (pegylation), which reduces IFN 
breakdown and clearance, thereby decreasing its immunoge-
nicity and increasing half-life, allowing less frequent weekly 
dosing schedules while sustaining high IFN levels.
The current standard of care for HCV monoinfection is 
pegylated IFN alfa and ribavirin (Manns et al 2001; Fried 
et al 2002). Regimens vary by HCV genotype: for geno-
types 1 or 4, ribavirin dosage is weight-based (1000 mg/day 
for weight 75 kg and 1200 mg/day for weight 75 kg), 
while for genotypes 2 or 3, a lower dose (800 mg/day) is 
prescribed. Similarly, duration of therapy is 48 weeks for 
patients with genotypes 1 or 4, and 24 weeks for patients 
with genotypes 2 or 3. These schedules have resulted in SVR 
rates ranging from 45% to 55% in groups with genotypes 1 
or 4, and as high as 80% in groups with genotypes 2 or 3. 
Weight-based dosing of ribavirin may add efﬁ  cacy to this 
antiviral regimen, especially in patients with higher BMI 
(Jacobson et al 2007). Factors associated with decreased 
response include African-American race, obesity, pres-
ence of cirrhosis, high viral loads (800,000 IU/mL), and 
genotypes 1 and 4.
Therapy of HIV – HCV coinfection
Published recommendations for treatment of HCV-HIV 
coinfected patients reach consensus on a standard of care Therapeutics and Clinical Risk Management 2008:4(4) 791
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of pegylated IFN and ribavirin for 48 weeks. These guide-
lines draw largely upon the results of 4 major randomized 
trials, the results of which were all published in 2004. These 
studies demonstrated a consistently superior overall efﬁ  cacy 
of pegylated IFN and ribavirin compared with standard IFN 
and ribavirin in coinfected patients. Nonetheless, overall SVR 
rates in the pegylated IFN and ribavirin treatment arms were 
signiﬁ  cantly lower than those reported for HCV monoinfec-
tion, particularly for genotypes 1 and 4. These pivotal trials 
will be described in further detail. (Table 1)
Barcelona
This single-center, open-label trial randomized 95 patients 
to IFN alfa-2b plus ribavirin or pegylated IFN alfa-2b plus 
ribavirin (Laguno et al 2004). Ribavirin was dose-adjusted 
by body weight (dose range 800–1200 mg/day). Subjects 
with favorable genotypes (2 and 3) and low HCV RNA 
level (800,000 IU/mL) were randomized to 24 weeks 
of treatment; all others received a full 48 weeks. Dose 
reduction was allowed for adverse effects according to a 
deﬁ  ned protocol. Patients with detectable HCV RNA after 
24 weeks of therapy were considered failures and therapy 
was discontinued.
By intention-to-treat analysis SVR was achieved in 
44% of the pegylated IFN group vs. 21% of the IFN group 
(p = 0.017). For patients with genotypes 1 and 4, SVR was 
38% for pegylated IFN vs. 7% for IFN (p = 0.007). For 
genotypes 2 and 3, rates of SVR were similar (53% vs 47% 
for pegylated IFN vs IFN, respectively, p = 0.73) and relapse 
rates approached 23%. On multivariate analysis, genotypes 
2 and 3, dose modiﬁ  cation, and pegylated IFN therapy were 
independent predictors associated with SVR.
APRICOT
This international, multicenter, randomized trial, the largest 
to date, randomized a total of 868 patients to 48 weeks of 
treatment with either IFN alfa-2 plus ribavirin, pegylated IFN 
alfa-2a plus placebo, or pegylated IFN alfa-2a plus ribavirin 
(Torriani et al 2004). Ribavirin daily dose was 800 mg for 
all patients. Dose reduction was allowed for adverse effects 
according to a deﬁ  ned protocol.
By intention-to-treat analysis, SVR was achieved in 
40% of the pegylated IFN plus ribavirin group, vs 20% of 
the pegylated IFN plus placebo group (p  0.001) and 12% 
of the IFN plus ribavirin group (p  0.001). For patients 
with genotype 1, SVR rates were 29% for the pegylated 
Table 1 Baseline characteristics and sustained virologic response rates in subjects randomized to pegylated interferon and ribavirin 
in four pivotal trials. Reprinted with permission from Shuhart MC. 2007. Hepatitis C and HIV coinfection. Curr Hepatitis Rep, 6:46–53. 
Copyright © 2005 Current Medicine Group LLC.
  APRICOT [45••]  Barcelona [46•]  ACTG [47•]  RIBAVIC [48•]
Subjects, N  289  52  66  205
Pegylated interferon  Alfa-2a  Alfa-2b  Alfa-2a  Alfa-2b
Ribavirin dose, mg/d  800  800, 1000 or 1200  600–1000 (escalated)  800
Age, y  39.7 (mean)  40 (mean)  45 (median)  39.5 (mean)
Male, %  80  63  79  77
African American, %  11  NR  32  NR*
Body weight, mean, kg  72.1  NR  NR  67.4
CD4 cell count, cells/μL  542 (mean)  570 (mean)  495 (median)  477 (median)
HIV RNA, % undetectable  60 (50 copies/mL)  70 (200 copies/mL)  61 (50 copies/mU  70 (400 copies/mL)
Antiretroviral therapy, %  84  88  85  83
HCV RNA level in high range, %  72 (800,000 lU/mL)  47 (800,000 IU/mL)  83 (1,000,000 IU/mL)  65 (500,000 IU/mL)
HCV genotype, %      
Genotype 1  61  55  77  48
Genotype 2 or 3  32  37  NR+ 38
Genotype 4  6  8  NR+ 13
Other 1  0  NR1 1
Bridging ﬁ  brosis/cirrhosis, %  12  30  11  39
Sustained response, %       
Genotype 1  29  38*  14  17‡
Genotype 2 or 3  62  53  73† 44
Genotype 4  NR  —  —  —
*6% not of French or Mediterranean descent.
†Non-1 genotypes were predominantly 2 or 3.
‡Genotypes 1 and 4 combined.
Abbreviations:   ACTC,   AIDS Clinical Trials Croup; APRICOT,   AIDS PECASYS Ribavirin International Co-infection Trial; HCV, hepatitis C virus; NR, not reported. Therapeutics and Clinical Risk Management 2008:4(4) 792
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IFN plus ribavirin group, 14% for the pegylated IFN plus 
placebo group, and 7% for the IFN plus ribavirin group. 
For patients with genotype 3, SVR rates were 62%, 36%, 
and 20%, respectively. HCV genotype other than 1 and 
baseline HCV RNA 800,000 IU/mL were associated with 
increased odds of SVR. Early virologic response (deﬁ  ned 
as a decrease in the HCV RNA level of 2 log or more by 
week 12) predicted a higher likelihood of SVR, particularly 
in the pegylated IFN plus ribavirin group. Only 2% of total 
patients who did not have early virologic response went on 
to have SVR.
Of note, the results of this trial were critical for US FDA 
approval of pegylated IFN alfa-2a and ribavirin for HCV-HIV 
coinfected patients. Additional APRICOT ﬁ  ndings published 
in 2006 indicated a histologic response, deﬁ  ned as 2 point or 
greater reduction in histological activity index (HAI) score, 
occurred in 69% of patients with SVR and 43% of patients 
without SVR.
ACTG
Published at the same time as the APRICOT study, this 
multicenter, randomized trial included a total of 133 patients 
who were randomized to receive pegylated IFN alfa-2a plus 
ribavirin or IFN alfa-2a plus ribavirin (Chung et al 2004). 
Ribavirin was dosed in escalating fashion from 600 to 1000 
mg daily in an attempt to reduce anemia. Dose reduction 
was allowed for adverse effects according to a deﬁ  ned pro-
tocol. Subjects with virologic response at week 24 continued 
treatment, and those without 24-week virologic response 
underwent liver biopsy and could only continue if they had 
histologic response (HAI improvement of at least 2 points). 
Primary end-points were virologic response and safety at 
week 24, and SVR was among the secondary end-points.
By intention-to-treat analysis, SVR rate was 27% in the 
pegylated IFN plus ribavirin group, compared with 12% in 
the IFN plus ribavirin group (p = 0.03). For genotype 1, SVR 
rates were 14% and 6%, respectively, whereas for non-
genotype 1, SVR rates were 73% and 33%, respectively. 
A relapse rate of 33% was observed in the pegylated IFN 
group, predominantly from genotype 1 patients, which partly 
explains the low SVR rate of 14%. Factors predictive of SVR 
in multivariate analysis included receipt of pegylated IFN, 
HCV genotype other than 1, absence of prior intravenous 
drug use, and detectable HIV-1 RNA at entry. None of the 
patients without early virologic response went on to have 
SVR (NPR 100%). Histologic responses were noted in 35% 
of virologic nonresponders and 52% of virologic responders, 
indicating a possible clinical beneﬁ  t even in the absence of 
virologic clearance, and suggesting a role for investigation 
of maintenance strategies.
RIBAVIC
This French multicenter, randomized open-label trial 
included a total of 412 patients who were randomized to 
receive pegylated IFN alfa-2b (1.5 μg/kg) plus ribavirin or 
IFN alfa-2b plus ribavirin for 48 weeks (Carrat et al 2004). 
Ribavirin daily dose was 800 mg. Liver biopsy was per-
formed at the end of follow-up. Dose reduction was allowed 
for adverse effects according to a deﬁ  ned protocol. By 
intention-to-treat analysis, SVR was obtained in 27% of the 
pegylated IFN plus ribavirin group and 20% of the IFN plus 
ribavirin group (p = 0.047). Less than 1% of the patients not 
achieving early viral response went on to have SVR. Among 
patients with genotype 1 or 4, 17% of the pegylated IFN plus 
ribavirin group had SVR, compared with 6% of the IFN plus 
ribavirin group (p = 0.006). For patients with genotype 2, 3, 
or 5, rates of SVR did not differ between the two treatment 
groups (44% vs 43%, respectively, p = 0.88). Predictors of 
SVR by multivariate analysis included HCV genotypes 2, 
3, or 5, no protease inhibitor treatment, age 40 years, and 
baseline alanine aminotransferase (ALT) greater than 3 times 
normal. Histologic beneﬁ  t was signiﬁ  cant only in those who 
had SVR. In contrast to the APRICOT ﬁ  ndings, only 4% 
of nonresponders had histologic improvement, deﬁ  ned as a 
decrease of 2 points or more of ﬁ  brosis stage.
These four pivotal trials, while demonstrating a beneﬁ  t of 
pegylated IFN alfa-2a or pegylated IFN alfa-2b in combina-
tion with ribavirin for HIV – HCV coinfected individuals, 
still had lower SVR rates than those for HCV monoinfec-
tion. SVR ranged from 27% to 44%. The higher SVR seen 
in the Barcelona study, which used ribavirin doses of up to 
1200 mg/day, suggests that the dose of ribavirin may play 
a critical role in determining SVR. The next trial pursues 
this hypothesis.
PRESCO
This Spanish multicenter trial aimed to evaluate the efﬁ  cacy 
and safety of weight-based RBV dosing as well as extended 
duration of therapy in coinfected patients (Nunez et al 2007a). 
A total of 389 patients all received pegylated IFN alfa-2a 
plus weight-based ribavirin at 1000 mg/day or 1200 mg/day. 
Patients without early virologic response (EVR) were 
discontinued, as were patients with detectable HCV RNA 
at 24 weeks. Genotype 2/3 patients were treated for 24 or 
48 weeks, and genotype 1/4 patients were treated for 48 or 
72 weeks. Dose reduction was allowed for adverse effects Therapeutics and Clinical Risk Management 2008:4(4) 793
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according to a deﬁ  ned protocol. By intention-to-treat analy-
sis, 49.6% of patients achieved SVR. SVR was signiﬁ  cantly 
more frequent in patients with HCV genotypes 2/3 (72.4%) 
than HCV genotypes 1/4 (35%) (p  0.0001). Overall, 
patients assigned to extended treatment arms demonstrated 
better treatment responses irrespective of genotype. How-
ever, 45% of patients allocated to the extended treatment 
arms refused to continue medication beyond the minimum 
period of therapy, mainly due to patient preference rather 
than serious adverse events. Deﬁ  nitive conclusions could 
not be drawn regarding beneﬁ  t of longer courses of therapy 
for patients without EVR, owing to the low number of such 
patients among HCV genotypes 2/3 and the low number of 
patients among HCV genotypes 1/4 completing extended 
therapy. Multivariate analysis identiﬁ  ed HCV genotypes 2/3, 
baseline HCV RNA 500,000 IU/mL, and negative HCV 
RNA at week 12 as independent predictors of SVR.
Predictors of response
Several factors in the above trials were identiﬁ  ed as predictors 
of SVR. Low pretreatment HCV RNA level, assignment 
to pegylated IFN, absence of prior intravenous drug use, 
baseline ALT  3 times normal, and no dose modiﬁ  cation 
were all associated with higher SVR. Interestingly, neither 
liver disease stage (all studies excluded only decompensated 
cirrhosis) nor baseline CD4 count at study entry was asso-
ciated with SVR in any of these studies. Perhaps the most 
striking ﬁ  nding was the absence of early virologic response 
as a predictor of SVR, with a negative predictive value of 
98%–100%, which seems to suggest that treatment can be 
discontinued early if EVR has not been reached.
Rapid virologic response (RVR), deﬁ  ned as an undetectable 
HCV RNA level at 4 weeks of therapy, has been shown to be 
another important predictor of response. Recently published 
data from the RIBAVIC study demonstrated that failure to 
suppress serum HCV RNA levels below 460,000 IU/mL after 
4 weeks of therapy was associated with a negative predictive 
value of 100% (Payan et al 2007). Similarly, the best positive 
and negative predictive values (97%) of SVR in the RIBAVIC 
trial were obtained in patients with RVR.
Certain factors have additionally been identified as 
predictors of virologic relapse following cessation of therapy. 
For instance, recently published PRESCO data indicates lack 
of RVR is an independent predictor of HCV relapse (relative 
risk [RR] 2.94; 95% conﬁ  dence interval [CI] 1.22–7.09; 
p = 0.02). Furthermore, use of concomitant HAART also 
was noted to be associated with relapse (p = 0.04) (Nunez 
et al 2007b). The nucleoside reverse transcriptase inhibitor 
abacavir has been implicated as an agent that should be 
particularly avoided during HCV therapy. When used 
concomitantly with ribavirin, abacavir is associated with a 
higher risk of early nonresponse to HCV therapy (RR 4.9) 
(Bani-Sadr et al 2007a). The PRESCO data reveal lower EVR, 
end of treatment response, and SVR in patients receiving 
abacavir-based antiretroviral therapy (Vispo et al 2007).
Toxicity
Interferon administration leads a variety of physical side effects 
which affect individuals with different frequency and severity. 
Early side effects include inﬂ  uenza-like symptoms such as 
myalgias, arthralgias, pyrexia, headache, and lassitude. These 
side effects tend to subside with longer duration of therapy 
and clearance of the drug from the system. On the other hand, 
weight loss has been a persistent and well-established side 
effect, with several studies demonstrating a signiﬁ  cantly higher 
incidence in coinfected patients receiving pegylated IFN plus 
ribavirin. One retrospective cohort study found that clinically 
signiﬁ  cant weight loss, deﬁ  ned as at least 5% of baseline 
weight, occurred in 76% of coinfected patients compared with 
39% of HCV-monoinfected patients (Re et al 2007). Similarly, 
the RIBAVIC investigators found that 29% of coinfected 
patients who received at least one dose of anti-HCV treatment 
developed severe weight loss (10% of baseline weight), and 
that these patients were signiﬁ  cantly more likely to develop 
lipodystrophy. Of note, weight loss of at least 5% that per-
sisted for 24 weeks after completion of anti-HCV therapy is 
associated with stavudine-based HAART, which has led some 
investigators to suggest a role for mitochondrial toxicity in the 
pathogenesis of weight loss (Bani-Sadr et al 2008a).
In addition to weight loss, more persistent side effects 
with repeated administration of anti-HCV therapy include 
fatigue, anorexia, and an assortment of neuropsychiatric side 
effects ranging from mild attention deﬁ  cits through emotional 
lability, anger, and depression. Suicide has been described 
resulting from IFN-related depression (Janssen et al 1994). 
Serotonin uptake inhibitors and other antidepressants have 
been used with success in ameliorating neuropsychiatric side 
effects (Schaefer et al 2005). In the coinfected individual, 
involvement of a treatment team, including psychiatric 
support, has been demonstrated to increase compliance to 
therapy. The use of such a team may also expand the poten-
tial pool of patients that can be considered for the rigors of 
antiviral treatment (Taylor et al 2003).
An issue unique to the coinfected patient and of considerable 
concern in early trials is the reduction of CD4+ count during 
therapy. Numerous investigators have noted a reduction in Therapeutics and Clinical Risk Management 2008:4(4) 794
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CD4+ counts during therapy, although adverse consequences 
of the reduction appear to be unusual (Soriano et al 2007a). 
CD4+ cell counts return to normal within 24 weeks of cessation 
of HCV therapy. The safety of HCV therapy in patients with 
baseline CD4+ counts below 200 cells/μL is not clear since 
the major clinical trials took such a count as exclusion criteria 
(Laguno et al 2004; Chung et al 2004; Carrat et al 2004). The 
exception was the APRICOT trial, where CD4+ count as low 
as 100 cells/μL was allowed (Torriani et al 2004).
Anemia, a commonly seen complication of anti-HCV 
therapy, has been observed in higher incidence in coinfected 
populations. In RIBAVIC, 16% of patients who received 
at least one dose of anti-HCV therapy developed severe 
anemia (Hb  10 g/dL). Multivariate analysis demonstrated 
a signiﬁ  cant risk associated with zidovudine use (odds ratio 
[OR] 3.27; 95% CI 1.64–1.54; p = 0.0008) (Bani-Sadr et al 
2007b). Moreover, concomitant use or zidovudine and 
anti-HCV therapy has been associated with higher rates of 
ribavirin dose reduction and use of epoetin alfa (Alvarez et al 
2006). These deleterious consequences may be related to 
zidovudine-induced reduction of globin mRNA synthesis or 
zidovudine-induced increases in plasma levels of ribavirin.
Drug-drug interactions are responsible for other con-
siderable toxicities in this population. Chief among these 
is mitochondrial toxicity from nucleoside analogue reverse 
transcriptase inhibitors (NRTIs), which may manifest symp-
tomatically with lactic acidosis, pancreatitis, weight loss, or 
even hepatic decompensation (Lafeuillade et al 2001). This 
toxicity is most pronounced in patients receiving concomi-
tant anti-HCV therapy and didanosine. The RIBAVIC trial 
demonstrated an adjusted 46-fold increase in the risk of 
symptomatic mitochondrial toxicity and an adjusted 8.8-fold 
increase in the risk of spontaneous hepatic decompensation 
in such patients (Bani-Sadr et al 2005a, b). Analysis of 
APRICOT data similarly identiﬁ  ed didanosine treatment as 
a risk factor for hepatic decompensation (Mauss et al 2004). 
Furthermore, didanosine use has been signiﬁ  cantly associated 
with worsening of liver ﬁ  brosis (OR 3.34; 95% CI 1.39–7.96; 
p = 0.007) in the RIBAVIC study population, prompting the 
authors to suggest that anti-HCV therapy should precede the 
administration of HAART (Bani-Sadr et al 2008b).
Earlier recognition of these drug interactions provided 
beneﬁ  t in subsequent studies. In particular, in the PRESCO 
trial, didanosine use was excluded, and only 2 patients stopped 
anti-HCV therapy due to symptomatic mitochondrial toxic-
ity, while there were no cases of hepatic decompensation. 
The authors conclude, “Avoidance of didanosine, limited 
use of zidovudine and therapy restricted to patients with 
CD4+ T-cell counts 300 cells/mL most probably explains 
the lower and different spectrum of serious adverse events in 
PRESCO compared with prior trials conducted in coinfected 
patients.” (Soriano et al 2007a).
On the basis of these known toxicities, a few recom-
mendations can be made for coinfected patients in whom 
anti-HCV therapy is to be initiated. If other antiretroviral 
regimens are available, zidovudine should be discontinued. If 
zidovudine must be continued, it is recommended to monitor 
hemoglobin levels closely for signiﬁ  cant anemia (Sulkowski 
2008). In the case of didanosine, concomitant treatment with 
ribavirin is contraindicated (Soriano et al 2007b).
Enhancing antiviral responses
Studies and experience with HCV mono-infected patients sug-
gest a number of details that can enhance response to antiviral 
therapy. Although it is clear that genotype 2 and 3 infected 
patients have higher rates of SVR, it has recently been noted 
that some patients with these “favorable” genotypes may 
require more extensive treatment than the currently recom-
mended 24 weeks (Berg et al 2006). Longer therapy has been 
suggested in those patients failing to reach the endpoint of 
early or rapid virologic response, while shorted duration has 
been suggested for genotype 2 and 3 patients with prompt 
eradication of circulating viremia (Dalgard and Mangia 2006). 
The use of weight-based ribavirin dosing, especially in heavier 
patients, may enhance response compared with ﬂ  at ribavirin 
dosing. The important contribution of ribavirin in providing 
virologic response necessitates extreme caution with, if not 
complete avoidance of, zidovudine and abacavir.
The use of growth factors, especially erythropoietin, 
can maintain hematocrit during therapy, but has yet to be 
deﬁ  nitively shown to enhance SVR rates. In the HIV – HCV 
coinfected patients, tailored duration of therapy and weight-
based ribavirin dosing have shown promise, but will require 
more rigorous scrutiny in the coming years. Erythropoietin 
has been shown to allow higher ribavirin rates and improved 
quality of life scores in coinfected patients on antiviral 
therapy and was well tolerated. Similar to the situation with 
monoinfected patients, erythropoietin has not been shown to 
effect SVR (Afdhal et al 2004; Sulkowski et al 2005).
Future therapeutic options
As the life cycle of HCV is better understood, the following 
model has been promulgated: HCV binding to a cell surface 
receptor, internalization into the host cell, cytoplasmic release 
and uncoating of the viral RNA genome, internal ribosome 
entry site-mediated translation and polyprotein processing by Therapeutics and Clinical Risk Management 2008:4(4) 795
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cellular and viral proteases, RNA replication, packaging and 
assembly, and virion maturation and release from the host 
cell (Moradpour and Blum 2004). A number of nonstructural 
proteins have been identiﬁ  ed and characterized, providing 
potential strategies for therapeutic intervention. For example, 
the NS3 serine protease (Lamarre et al 2003) and the NS5B 
RNA dependent RNA polymerase (Lesburg et al 1999) have 
emerged as potential targets for antiviral therapies. Drug 
development has been hampered by the difﬁ  culty of the HCV 
protease binding site, viral mutation and the development of 
toxicity in animal trials. To date several drugs are emerging 
from phase II clinical trials into larger studies. It is becoming 
apparent that combination therapy with a number of antiviral 
drugs and perhaps immunomodulatory agents will be required 
to supplant IFN as the therapy of choice. The use of these newer 
agents in coinfected patients has not yet been reported.
Conclusions
The existing literature deﬁ  nitively demonstrates that optimal 
treatment of HCV in HIV-HCV coinfected patients requires 
the combination of pegylated IFN with ribavirin. Furthermore, 
the overall response rates are lower than in patients with HCV 
alone, particularly for patients with HCV genotype 1 or high 
pretreatment viral load. Predictors of response include geno-
type, baseline HCV RNA level, and undetectable HCV RNA 
at week 4. The newer PRESCO data indicate that weight-based 
ribavirin dosing results in higher SVR rates, though still less 
than those for HCV-monoinfected patients, and does not cause 
higher toxicity. Pegylated IFN combined with weight-based 
ribavirin is appropriate and safe for treatment of HCV in HIV-
HCV coinfected patients. Nucleoside reverse transcriptase 
inhibitors, including abacavir, zidovudine, and especially 
didanosine, should be discontinued before initiation of ribavi-
rin therapy. Patients infected with HCV genotypes 2 and 3 and 
RVR could beneﬁ  t from shorter (24 weeks) courses of therapy, 
based on PRESCO data, but current consensus guidelines still 
mandate 48 weeks for all patients, regardless of genotype. 
Similarly, patients with HCV genotypes 1 and 4 and early 
or slow virologic response, but not RVR, may beneﬁ  t from 
extended (60–72 weeks) courses of therapy. Patients without 
early virologic response at 12 weeks should be advised of 
the extremely low likelihood of SVR, and discontinuation of 
therapy should be considered, until results of ongoing main-
tenance trials are available. The demonstration of histologic 
response even in the absence of SVR does provide a rationale 
for maintenance therapy currently being evaluated.
Finally, newer agents that have speciﬁ  c activity against 
the HCV virion are currently in phase 1 and 2 trials. Targets 
such as the serine protease and the RNA-dependent RNA 
polymerase proteins are similar to those of HAART therapy 
in the HIV virion, suggesting possible overlap in coinfected 
patients. Further studies will certainly be needed to elucidate 
the nature of such an interaction.
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